The following Life Sciences practice note Produced in partnership with Daniel Bouthillier, Ma’n H. Zawati and Yann Joly provides comprehensive and up to date legal information covering:
Personalised medicine has existed for quite some time. Physicians have, to varying degrees, adapted treatments to individual patients based on information collected about them. But over the last decade and a half, the advent of systems biology has significantly widened the scope of personalised medicine, which in modern practice relies on acquiring as much data as possible about a given biological system.
The goal of personalised medicine is to interpret collected datasets in a way that improves our understanding of a living system and its pathologies while enabling targeted treatment that is responsive to an individual patient or group of patients. Personalised medicine is often portrayed as medicine that is ‘custom-made’, in opposition to traditional medicine that has a ‘one size fits all’ character. Personalised medicine includes all stages of medical procedure, beginning with diagnosis (often molecular diagnosis using biomarkers) and ending with targeted medicinal treatments. For many, personalised medicine may be defined as the effort of giving the right treatment to the right patient, with the right medicinal product, at the right time, and for the right duration.
But according to some experts, this definition is too restrictive. To them, personalised medicine is not limited to genetic testing, genome sequencing, or particular medicinal products that are responsive to specific biomarkers. Their alternative definition incorporates big data, internet or computer-connected personal medical devices,
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
The principle of transferred maliceIf a person has a malicious intent towards X and, in carrying out that intent, injures Y, he is guilty of an offence. So, if D shoots at A with intent to kill him but kills B by mistake it is murder; the mistake as to the identity of the victim is irrelevant as D
Having established that a duty of care exists (see Practice Note: Negligence—when does a duty of care arise?), it is then necessary to consider whether or not there has been a breach of that duty. This will depend on a number of factors outlined below and considered against the general background of
STOP PRESS: The Corporate Insolvency and Governance Act 2020 contains provisions which, on a temporary basis (presently until 31 December 2020) impose significant limitations on the ability for a creditor to seek a winding-up order against a company. For further reading, see Practice Note: Corporate
Case number [insert number][In the principal registryORIn the [insert court location] FAMILY court]Sitting at [insert place]Notice of actingBetween[insert petitioner name]Petitionerand[insert respondent name]RespondentTake notice that we [insert name of firm] have been appointed to act as the
0330 161 1234
To view our latest legal guidance content,sign-in to Lexis®PSL or register for a free trial.